Viking claims NASH win af­ter meet­ing pri­ma­ry end­point in PhI­Ib study

More than three years af­ter kick­ing off a Phase IIb tri­al in biop­sy-con­firmed non­al­co­holic steato­hep­ati­tis (NASH), Viking Ther­a­peu­tics says it has a topline win.

The San Diego biotech said Tues­day that the tri­al for thy­roid hor­mone re­cep­tor be­ta ag­o­nist VK2809 met the pri­ma­ry end­point of re­duc­ing liv­er fat con­tent from base­line af­ter 12 weeks com­pared to place­bo. The drug is Viking’s lead can­di­date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER